Veterinarians & Veterinary Oncologists - Librela Cancer Concerns

Veterinarians / veterinary oncologists concerned about Librela and cancer I am specifically looking to hear from veterinarians, veterinary oncologists, or researchers who believe or seriously suspect that Librela (bedinvetmab) may contribute to the development, growth, or progression of cancer. I am not looking for general reassurance that Librela is considered safe. I specifically want to understand the medical and biological reasoning of professionals who have concerns about this drug. One of my biggest concerns is that Librela is used primarily in older dogs. In that population, serious new illnesses, rapid decline, cancer, or death can easily be attributed to age or pre-existing disease. That makes it extremely difficult to know whether a true safety signal is being missed. Older dogs may still have months or years of good quality life ahead of them. Their age should not automatically make severe disease, metastasis, rapid deterioration, or a painful death seem expected or acceptable. If you believe Librela could potentially influence cancer development or tumor progression, I would especially like to understand: What biological mechanism could explain it? Could NGF inhibition, TrkA/p75NTR signaling, angiogenesis, immune surveillance, or the tumor microenvironment be involved? Have you observed cancer or unusually rapid tumor progression in dogs receiving Librela? Have you seen hemangiosarcoma specifically? I am particularly interested in hearing from professionals who are skeptical of Librela or who have stopped using it because of what they have observed in practice.